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Although it is known that 1-methylnicotinamide (MNA) displays vasoprotective activity
in mice, as yet the effect of MNA on endothelial function has not been demonstrated
in vivo. Here, using magnetic resonance imaging (MRI) we profile the effects of MNA
on endothelial phenotype in mice with atherosclerosis (ApoE/LDLR−/−) in vivo, in
comparison to angiotensin (Ang) -converting enzyme (ACE) inhibitor (perindopril), with
known vasoprotective activity. On a biochemical level, we analyzed whether MNA- or
perindopril-induced improvement in endothelial function results in changes in ACE/Ang
II-ACE2/Ang-(1–7) balance, and L-arginine/asymmetric dimethylarginine (ADMA) ratio.
Endothelial function and permeability were evaluated in the brachiocephalic artery (BCA)
in 4-month-old ApoE/LDLR−/− mice that were non-treated or treated for 1 month
or 2 months with either MNA (100 mg/kg/day) or perindopril (10 mg/kg/day). The
3D IntraGate R©FLASH sequence was used for evaluation of BCA volume changes
following acetylcholine (Ach) administration, and for relaxation time (T1) mapping
around BCA to assess endothelial permeability using an intravascular contrast
agent. Activity of ACE/Ang II and ACE2/Ang-(1–7) pathways as well as metabolites
of L-arginine/ADMA pathway were measured using liquid chromatography/mass
spectrometry-based methods. In non-treated 6-month-old ApoE/LDLR−/− mice, Ach
induced a vasoconstriction in BCA that amounted to –7.2%. 2-month treatment with
either MNA or perindopril resulted in the reversal of impaired Ach-induced response to
vasodilatation (4.5 and 5.5%, respectively) and a decrease in endothelial permeability (by
about 60% for MNA-, as well as perindopril-treated mice). Improvement of endothelial
function by MNA and perindopril was in both cases associated with the activation of
ACE2/Ang-(1–7) and the inhibition of ACE/Ang II axes as evidenced by an approximately
twofold increase in Ang-(1–9) and Ang-(1–7) and a proportional decrease in Ang II and
Frontiers in Pharmacology | www.frontiersin.org 1 April 2017 | Volume 8 | Article 183
fphar-08-00183 April 7, 2017 Time: 16:52 # 2
Bar et al. Functional and Biochemical Endothelial Profiling In Vivo
its active metabolites. Finally, MNA and perindopril treatment resulted in an increase in
L-arginine/ADMA ratio by 107% (MNA) and 140% (perindopril), as compared to non-
treated mice. Functional and biochemical endothelial profiling in ApoE/LDLR−/− mice
in vivo revealed that 2-month treatment with MNA (100 mg/kg/day) displayed a similar
profile of vasoprotective effect as 2-month treatment with perindopril (10 mg/kg/day):
i.e., the improvement in endothelial function that was associated with the beneficial
changes in ACE/Ang II-ACE2/Ang (1–7) balance and in L-arginine/ADMA ratio in plasma.
Keywords: endothelial function, atherosclerosis, MRI, 1-methylnicotinamide, perindopril, plasma angiotensin
profile, L-Arg/ADMA ratio
INTRODUCTION
1-Methylnicotinamide (MNA), the major metabolite of NA
synthesized in the liver in the reaction involving NNMT,
when given exogenously has distinct therapeutic activity, despite
the fact, that it has long been considered inactive (Aksoy
et al., 1994). Indeed, topical MNA alleviates the inflammatory
responses in skin diseases such as acne, contact dermatitis
or rosacea (Gebicki et al., 2003; Wozniacka et al., 2005). In
turn, systemic administration of MNA exerts anti-thrombotic
(Chlopicki et al., 2007), anti-inflammatory (Bryniarski et al.,
2008), and gastroprotective (Brzozowski et al., 2008) properties
mediated by the activation of COX-2 and PGI2 pathways.
Furthermore, MNA can improve endurance exercise capacity in
mice with diabetes, and may decrease the cardiovascular risk of
exercise (Przyborowski et al., 2015). MNA was demonstrated to
have hepatoprotective activity against concanavalin A-induced
liver injury through the downregulation of IL-4 and TNF-α
signaling (Sternak et al., 2010; Jakubowski et al., 2016), and to
inhibit metastasis formation in a murine model of metastatic
mammary gland cancer (4T1) in BALB/c mice (Blazejczyk
et al., 2016). Interestingly, 1-MNA has also been shown
to restore endothelial function in diabetic hypertriglycemic
rats (Bartuś et al., 2008) analyzed ex vivo in isolated aorta,
suggesting that the improvement in endothelial function may
represent an important target of MNA activity and may explain
therapeutic efficacy of MNA in various diseases including
diabetes (Watała et al., 2009) and atherosclerosis (Mateuszuk
et al., 2016). Indeed, in our recent study anti-atherosclerotic
effects of MNA in ApoE/LDLR−/− mice, including the inhibition
Abbreviations: ACE, angiotensin-converting enzyme; ACE-I, angiotensin-
converting enzyme inhibitor; Ach, acetylcholine; ACN, acetonitrile; ADMA,
asymmetric dimethylarginine; Ang, angiotensin; ApoE/LDLR−/−, atherosclerotic
mice; Arg, arginine; BCA, brachiocephalic artery; CA, contrast agent; COX-2,
cyclooxygenase 2; CS, calibration standards; DDAH, dimethylarginine
dimethylaminohydrolase; ECs, endothelial cells; eNOS, endothelial nitric
oxide synthase; FA, formic acid; Hcy, homocysteine; HFD, high-fat diet; IL-4,
interleukin-4; IS, internal standard; LC-MS/MS, liquid chromatography-tandem
mass spectrometry; Met, L-methionine; MNA, 1-methylnicotinamide; MRI,
magnetic resonance imaging; MRM, multiple reaction monitoring mode;
NA, nicotinamide; NFPA, nonafluoropentanoic acid; NNMT, nicotinamide
N-methyltransferase; NO, nitric oxide; Npx50, number of pixels, for which T1 had
changed more than 50% after contrast agent administration; PGI2, prostacyclin;
QC, quality control samples; RAS, renin-angiotensin system; ROI, region of
interest; ROS, reactive oxygen species; RS, real samples; SDMA, symmetric
dimethylarginine; VFA, Variable Flip Angle technique; VSMCs, vascular smooth
muscle cells; T1, relaxation time; TNF-α, tumor necrosis factor-α.
of inflammatory burden in plaques, diminished systemic
inflammation, diminished platelet activation that were associated
with an improvement in PGI2 and NO-dependent endothelial
function. These results support the notion that pronounced
effects of MNA on endothelial function could contribute to
therapeutic efficacy of MNA (Mateuszuk et al., 2016). However,
in none of the previous experimental studies of MNA was
endothelial function assessed in vivo, but only in ex vivo vascular
preparation (Bartuś et al., 2008; Mateuszuk et al., 2016).
Endothelial dysfunction, being a consequence of vascular
homeostatic imbalance is a hallmark of various cardiovascular
diseases including atherosclerosis (Anderson et al., 1995),
hypertension (Dharmashankar and Widlansky, 2010), heart
failure (Marti et al., 2012), as well as non-cardiovascular
diseases such as cancer (Franses et al., 2013). Vascular
dysfunction is associated with activation of pro-inflammatory
signaling molecules including adhesion molecules, chemokines
and cytokines (Karbach et al., 2014; Steven et al., 2015).
There is also evidence that ROS play an important role in
vascular inflammation (Zhou et al., 2011) and tissue damage
(Mittal et al., 2014). There are number of enzymatic sources
of endothelial ROS, including eNOS uncoupling, converting
beneficial NO synthase into a detrimental superoxide-producing
enzyme (Karbach et al., 2014; Schulz et al., 2014).
Currently, many biochemical assays and functional tests are
used for the evaluation of impaired NO-dependent function,
oxidant stress and pro-inflammatory phenotype of endothelial
dysfunction in humans. Prognostic value of biochemical
measurements of endothelial biomarkers is still not widely
accepted (Walczak et al., 2015). However, endothelial function
measurements based on the assessment of impairment of
NO-dependent vasodilatation in the coronary and peripheral
circulation have prognostic importance in predicting adverse
cardiovascular events (Schächinger et al., 2000; Halcox et al.,
2002). In particular, a non-invasive endothelial function
assessment, based on monitoring the brachial artery diameter
with a two-dimensional ultrasound, before and after artery
occlusion is considered a gold-standard method (Frolow et al.,
2015). MRI has also successfully been used for non-invasive
measurement of FMD in humans (Lee et al., 2007; Canton et al.,
2012; Redheuil, 2014; Teixido-Tura et al., 2014), but studies of
endothelial functional phenotype in mice in vivo are associated
with greater technical challenges (Botnar and Makowski, 2012).
Given high spatio-temporal resolution of MRI, it seems to be the
method of choice to assess endothelium-dependent response in
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mice. Indeed, MRI-based tests could provide an excellent tool
to gain better insight into endothelium-dependent mechanisms
in experimental studies in mice (Gotschy et al., 2013; Herold
et al., 2009). Phinikaridou et al. (2012) were the first to describe
an MRI-based method for the noninvasive assessment of
endothelial-dependent vasodilatation and permeability in vivo in
mice, with the use of an albumin-binding magnetic resonance
CA. In our recent studies, we developed a 3D MRI-based
assessment of endothelium-dependent vasodilatation induced by
acetylcholine (Ach) and endothelial permeability fully based on
the use of retrospectively self-gated 3D gradient-echo sequence
(Bar et al., 2016). The developed approach has been validated in
two distinct murine models of endothelial dysfunction, including
atherosclerotic (ApoE/LDLR−/− mice) and HFD-fed mice,
showing that our approach allows for a reliable detection of the
impairment of NO-dependent vasodilatation and changes in
endothelial permeability.
Genetically modified mice without apolipoprotein E and
receptor for low density lipoprotein (mouse apolipoprotein
E-deficient and Low-Density Lipoprotein Receptor-Deficient
Double Knockout, ApoE/LDLR−/−), constitute reliable mouse
model of endothelial dysfunction linked to atherosclerosis.
In this strain of mice, spontaneously atherosclerosis develops
without administration of atherogenic diet (Kostogrys et al.,
2012), and endothelial dysfunction precedes the atherosclerotic
plaque development (Csányi et al., 2012), similarly as it occurs
in humans. In turn, the early development of endothelial
dysfunction in single ApoE−/− mice was not univocally accepted
(Crauwels et al., 2003; Villeneuve et al., 2003).
Given that the assessment of the endothelial phenotype in vivo
in a reliable mouse model of endothelial dysfunction is essential
for the preclinical profiling of vasoprotective compounds, the
aim of the present study was to take advantage of the 3D
MRI-based method to profile effects of MNA on functional
phenotype of endothelium in ApoE/LDLR−/− mice in vivo, in
comparison to standard vasoprotective treatment such as ACE-I
(perindopril), that is known to display significant vasoprotective
effect in various experimental models including atherosclerosis
(Chłopicki and Gryglewski, 2005). We also analyzed whether
MNA- or perindopril-induced improvement in endothelial
function is associated with biochemical changes in plasma
in ACE/Ang-II-ACE2/Ang-(1–7) balance and L-Arg/ADMA
ratio.
MATERIALS AND METHODS
Animals
In this study, 4-month-old ApoE/LDLR−/− mice (body weight
of 20–30 g), bred in the Department of Human Nutrition,
University of Agriculture (Krakow, Poland), were transported
to the animal house at Jagiellonian Centre for Experimental
Therapeutics (JCET), Jagiellonian University (Krakow, Poland)
and were treated for 1 or 2 months with MNA (syntethized
by dr Jan Adamus, Technical University in Lodz, Poland:
100 mg/kg/day in diet) or perindopril (a gift from Servier,
Warszawa Poland: 10 mg/kg/day in drinking water). Doses of
compounds used in this study were based on our previous
published (Chlopicki et al., 2007; Mateuszuk et al., 2016) and
unpublished studies, for MNA and perindopril, respectively.
Two groups of 4-month-old ApoE/LDLR−/− mice were left
untreated (as control groups) for 1 and 2 months, respectively.
The sizes and names of the experimental groups are reported
in the legends of the corresponding graphs. All mice were
bred in standard conditions (LD: 12/12, humidity: 60%,
temperature: 23◦C), and housed in pathogen-free conditions.
Prior to the MRI experiment, the animals were transported
to the animal house at the Institute of Nuclear Physics
(Krakow, Poland) to assess endothelial phenotype in vivo.
After in vivo measurements, mice were sacrificed in order
to collect blood. The experimental design is illustrated in
Supplementary Figure S1. All experiments were approved by
the Ethics Local Committee of Jagiellonian University (Krakow,
Poland) and were compliant with the Guide for the Care and
Use of Laboratory Animals of the National Academy of Sciences
(NIH publication No. 85–23, revised 1996).
In Vivo Assessment of NO-dependent
Endothelial Response to Ach and
Endothelial Permeability by MRI
MRI experiments were performed using a 9.4T scanner (BioSpec
94/20 USR, Bruker, BioSpin GmbH, Germany), as described
previously (Bar et al., 2016). Mice were anaesthetized using
isoflurane (Aerrane, Baxter Sp. z o. o., Warszawa, Poland, 1.7
vol. %) in an oxygen and air (1:2) mixture. Body temperature
was maintained at 37◦C using circulating warm water. ECG,
respiration and body temperature were monitored using a Model
1025 Monitoring and Gating System (SA Inc., Stony Brook,
NY, USA). Mice were imaged in the supine position to test the
vasomotor response of the vessel. 3D images of the aortic arch
prior to and 25 min after intraperitoneal Ach administration
(Sigma–Aldrich, Poznan Poland: 50 µl, 16.6 mg/kg) were
acquired using the cine IntraGateTM FLASH 3D sequence and
reconstructed with the IntraGate 1.2.b.2 macro (Bruker, BioSpin
GmbH, Germany). T1 maps were measured before and 30 min
after intravenous administration of albumin-binding gadolinium
CA (Galbumin, BioPal, Worcester, MA, USA – 25 mg/ml,
4.5 ml/kg) using the VFA technique (Cheng and Wright, 2006;
Wang et al., 2006), by sampling the signal, using varying values
of flip angles and then fitting the result to an expected T1-
dependent signal model. Imaging parameters for endothelial
function assessment included the following: repetition time
(TR) – 6.4 ms, echo time (TE) – 1.4 ms, field of view (FOV) –
30 mm × 30 mm × 5 mm, matrix size – 256 × 256 × 30,
flip angle (FA) – 30◦, and number of accumulations (NA) –
15, reconstructed to seven cardiac frames. Total scan time
was 10 min. Imaging parameters for endothelial permeability
assessment included the following: TR – 10 ms, TE – 1.1 ms,
FOV – 30 mm × 30 mm × 4 mm, matrix size – 192 × 160 × 8,
number of repetitions – 12, and reconstructed to one cardiac
frame. Eight FA were used: 2◦, 4◦, 6◦, 8◦, 14◦, 20◦, 30◦, 50◦. FA
values were set by changing the length of a radiofrequency pulse,
with constant amplifier power. Total scan time for all angles was
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FIGURE 1 | Methodology to assess endothelium-dependent response and changes in endothelial permeability in brachiocephalic artery (BCA)
in vivo by MRI. (A) Coronal view of the heart. Image showing position of the imaging layer (IL) used for 3D imaging of the aortic arch. (B) 3D image of aortic arch
acquired with the cine IntraGate R© FLASH 3D sequence. Endothelial function assessment, expressed as changes in the vessels volume (V) can be performed in
vessels arising from aortic arch. The end-diastolic volumes of BCA were assessed prior to and 25 min after intraperitoneal Ach administration. (C) Representative
images of vessels cross-sections, in which a number of pixels, for which T1 had changed more than 50% after CA administration (Npx50), is marked in red. BCA is
indicated as 1, left carotid artery (LCA) as 2, left subclavian artery (LSA) as 3. RV, right ventricle; LV, left ventricle.
16 min. The experimental design is illustrated in Supplementary
Figure S1.
MRI Data Analysis
Time-resolved 3D images of the aortic arch (Figure 1A) were
analyzed to endothelial function assessment in BCA, using
ImageJ software 1.46r (NIH Bethesda, MD, USA) and scripts
written in Matlab (MathWorks, Natick, MA, USA). Images
were reconstructed to seven cardiac frames and imported into
ImageJ as a hyperstack (Figure 1B matrix: 256 × 256, slices:
30, frames: 7). Further analysis was performed in diastole
of BCA, using small hyperstack (Figure 1B marked in red
color matrix: 256 × 256, slices: 5, frames: 1) starting at the
base of the vessel and ending just before the branch. Cross-
sectional areas of BCA at each slices were obtained using
thresholding segmentation and exported to Matlab, where BCA
volumes were reconstructed and calculated. Detailed analysis was
described in Supplementary Material of our previous work (Bar
et al., 2016). In order to endothelial permeability assessment,
obtained images were used to calculate the T1 around the BCA
lumen before and after CA administration. The signal model
was fitted pixel by pixel using Matlab software developed in
house. Two T1 maps (before and after CA administration)
were compared, using scripts written in Matlab, and pixels
for which T1 had changed significantly (by more than 50%)
after CA administration were marked in red (Figure 1C). The
threshold value (50%) was determined experimentally. All red
pixels were counted by program as number of pixels, for
which T1 had changed more than 50% after CA administration
(Npx50).
Measurement of Ang Profile in Plasma
The blood was drawn from the heart, collected in tubes
containing heparin (20 units/ml) and immediately mixed with
protease inhibitor cocktail (Sigma–Aldrich, Poznan, Poland)
in a ratio of 19:1 (v/v), and centrifuged at 1,000 × g for
10 min to isolate plasma. Afterward, the resulting plasma was
transferred into Protein LoBind tubes (Eppendorf, Hamburg,
Germany), split into aliquots and stored frozen at −80◦C until
analysis.
Protein precipitation with ACN was used as the sample
pre-treatment method to remove high molecular plasma
compounds. CS, QC samples, and RS were created by spiking
25 µl (pooled blank – CS, QC) plasma with 20 µl appropriate
working standard solution or water (RS) and 5 µl IS – [Asn1,
Val5]-Ang II (2,500 pg/ml). Calibration curve standards were
made at: 10; 50; 100; 250; 300; 400; 500 pg/ml (IS – 250 pg/ml)
concentrations, respectively. CS at seven different concentration
levels or adequate QC and RS were deproteinized with ACN
(in 4:1 (v/v) proportion to the samples used) and assayed.
The LC-MS/MS analyses of plasma samples were performed
on an UltiMate 3000 Rapid Separation nano-LC system (Dionex,
Thermo Scientific, San Jose, CA, USA) interfaced via a
ChipMateTM nanoelectrospray ion source (Advion, USA) to
a TSQ Vantage triple quadrupole mass spectrometer (Thermo
Scientific). The samples were injected in 5 µl aliquots onto a
trapping column for desalting and concentrating of the analytes
which in the next step was switched in-line with the separation
C18 column to elute the peptides at a flow rate of 300 nl/min with
an increasing percentage of the organic solvent. Separation was
accomplished using a gradient of phase A (acetic acid (1%, v/v)
in H2O) and phase B (acetic acid (1%, v/v) in ACN) as follows:
2% B for 5 min, 2–98% B for 15 min, and 98% B for 5 min. The
mass spectrometer was operated in the positive ion mode and the
detection of Ang peptides in MRM mode was performed. The two
most sensitive/specific ion transitions were measured for each of
the 9 Ang peptides determined [Ang I, II, III, IV, (1–7), (1–9),
Ang A, alamandine and Ang-(1–12)]. Analytical method details
as well as the MS/MS transitions monitored in the protocol are
described elsewhere (Olkowicz et al., 2016). Instrument control,
data collection, and analysis were achieved with the Thermo
Xcalibur (version 2.1) software.
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Measurement of Flux Through L-Arg
Metabolic Pathways
Plasma amino acid concentrations were determined using
a Surveyor HPLC system (Thermo Scientific) coupled to a
TSQ Vantage Triple-Stage Quadrupole mass spectrometer, as
described recently (Smolenska et al., 2016). Briefly, an aliquot
of plasma (50 µl) was deproteinized with 100 µl of ACN
maintained in ice. The tubes were then centrifuged at 4◦C,
16,000 × g for 10 min and the resultant supernatant was
collected and subjected to freeze-drying. The residue was
next reconstituted with 50 µl of H2O acidified with 0.1%
(v/v) FA and analyzed using an LC/MS system as detailed
below.
Chromatographic separation was achieved using a Synergi
Hydro-RP column (50 mm × 2.0 mm i.d., 2.5 µm) fitted
with a security guard (Phenomenex, Torrance, CA, USA).
The mobile phase consisted of a mixture of phase A (5 mM
NFPA in water) and phase B (0.1% (v/v) FA in ACN), that
was delivered at 0.2 ml/min in a gradient from 0 to 45% B
in 5.5 min. The effluent of the HPLC column was directed
to the electrospray Ion-Max source of the mass spectrometer
that was operated in MRM mode. The settings of the ion
source were as follows: needle voltage, +4.5 kV; sheath
gas pressure, 30 (arbitrary units); auxiliary gas pressure, 3
(arbitrary units), and capillary temperature, 250◦C. Additionally,
to overcome the possible reduction of the signal intensity
due to perfluorinated carboxylic acid use, we added 0.05%
(v/v) FA in methanol at 0.2 ml/min as the post-column sheet
flow. The LC/MS system, data acquisition and processing
were managed by the Xcalibur software (v. 2.1, Thermo
Scientific).
Statistical Analysis
All of the data obtained are presented as mean and standard
error of the mean (SEM) or in case of the lack of normal
distribution as median and range. Statistical tests were
done using STATISTICA 10 (Stat Soft Inc., USA) or
GraphPad Prism 5 (GraphPad Software, Inc., CA, USA)
software. Non-parametric test (Kruskal–Wallis test) or
parametric test (one-way ANOVA followed by Tukey’s post
hoc test) were performed. Pearson or Spearman correlation
coefficient tests were used to assess dependence between
two parameters. Statistical significance was defined as
p < 0.05.
RESULTS
Effects of MNA and Perindopril
Treatment on Endothelium-dependent
Vasomotor Response and Changes in
Endothelial Permeability in
ApoE/LDLR−/− Mice In Vivo
In non-treated ApoE/LDLR−/− mice, injection of Ach
(16.6 mg/kg given i.p. in the volume of 50 µl) resulted in
vasoconstriction of BCA. Endothelium-dependent response
of BCA after Ach administration amounted to –2.39 and –
7.18% for 5-month-old and 6-month-old ApoE/LDLR−/−
mice, respectively. In mice treated with MNA or perindopril
for a 1-month period (Figure 2A), endothelium-dependent
response improved and an increase in volume of BCA after
Ach injection was observed (by about 9 and 3%, respectively).
Treatment of ApoE/LDLR−/− mice for 2 months with MNA
or perindopril further improved endothelium-dependent
vasodilation as well as decreased endothelial permeability
(Figure 2B). The number of pixels around BCA, for which T1
had changed more than 50% after CA administration (Npx50)
was smaller in mice treated with MNA and perindopril than in
non-treated ApoE/LDLR−/− mice (Npx50 was 6.0, 6.0, and 15.0,
respectively, Figure 2B). Interestingly, there was a significant
correlation between endothelium-dependent response of BCA
and Npx50 (Table 1).
FIGURE 2 | Effects of MNA and ACE-I (perindopril) treatment on endothelial function and permeability in vivo in ApoE/LDLR−/− mice. Changes in
end-diastolic volume of BCA 25 min after Ach administration (A) and number of pixels around BCA, for which T1 had changed more than 50% after CA
administration (Npx50) (B) in non-treated ApoE/LDLR−/− mice (columns with diagonal lines) and in ApoE/LDLR−/− mice treated with MNA (black columns) or
perindopril (columns with vertical lines) for one month (Untreated_5m n = 8, perindopril n = 5, MNA n = 6) or two months (Untreated_6m n = 8, perindopril n = 9,
MNA n = 7). Statistics: Kruskal–Wallis test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
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TABLE 1 | Correlation between parameters of functional and biochemical
endothelial profiling in vivo.
The pair of parameters R Spearman p
BCA volume changes and Npx50 –0,668739 0,000668
BCA volume changes and L-arginine/ADMA ratio 0,765473 0,000000
BCA volume changes and Ang-(1–7)/Ang II ratio 0,710365 0,000001
Npx50 and L-arginine/ADMA ratio –0,770589 0,000070
Npx50 and Ang-(1–7)/Ang II ratio –0,639038 0,002420
Effects of MNA and Perindopril
Treatment on Plasma Ang Profile
The pattern of changes in plasma Ang profile of ApoE/LDLR−/−
mice treated for one month with MNA was largely convergent
with those observed in plasma of mice treated with perindopril
(as compared to non-treated animals), and involved an
increase in concentration of Ang-(1–7) [by 36% (MNA), 95%
(perindopril)], alamandine [by 18% (MNA), 47% (perindopril)],
and Ang-(1–9) [by 72% (MNA), 173% (perindopril)] in
comparison to untreated ApoE/LDLR−/− mice (Figure 3A).
At the same time, the level of Ang II and other pathological
effectors of the RAS (Ang III, IV, A) significantly decreased.
The most pronounced differences were observed in the content
of Ang II and its N-terminally truncated metabolite – Ang III,
the level of which nearly halved as compared to the control,
untreated animals [from 119.8 ± 11.3 to 85.5 ± 5.4 (MNA) and
to 50.2± 4.1 (perindopril) fmol/ml for Ang II, from 206.2± 15.5
to 130.4 ± 10.0 (MNA), and to 96.2 ± 8.7 (perindopril) fmol/ml
for Ang III, respectively]. These changes were accompanied by
a slight increase in the content of precursor peptides: Ang I [by
21% (MNA) and 34% (perindopril) versus non-treated mice] and
Ang-(1–12) [by 18% (MNA) and 43% (perindopril) as compared
to control animals]. Activation of counter-regulatory ACE2/Ang-
(1–7)/Ang-(1–9) axis with concomitant inhibition of ACE/Ang II
pathway was further highlighted after two months of treatment
with MNA or perindopril whereby the beneficial effect of MNA
treatment was even more similar to that exerted by perindopril
(Figure 3B). Interestingly, there was a significant correlation
between Ang-(1–7)/Ang II ratio and endothelium-dependent
response of BCA or Npx50 (Table 1).
Effects of MNA and Perindopril
Treatment on L-Arg/ADMA Ratio in
Plasma
Endothelial function is critically dependent on eNOS activity
and consequently adequate NO bioavailability. Treatment with
both MNA and perindopril was associated with alterations in
amino acid metabolism engaged in NO generation. Plasma
concentration of L-Arg that serves as a substrate for the
formation of NO by the NOS enzymes was elevated after
just one month of treatment with both MNA (by 25%) and
perindopril (21%) as compared to untreated ApoE/LDLR−/−
mice (Figure 4A). Furthermore, the plasma concentration of
precursors of L-Arg (L-citrulline and L-ornithine) was increased
in parallel. These changes were accompanied by a decrease
in methylated Arg concentration. After 1 month of treatment,
ADMA that is perceived as an endogenous inhibitor of all NOS
enzymes (including eNOS) was diminished by 10% (MNA) and
17% (perindopril), respectively (in comparison to non-treated
animals). Two months of pharmacotherapy led to a further
decline in the plasma concentration of ADMA [by 15% (MNA)
and by 20% (perindopril), respectively] (Figure 4B). Plasma
concentration of SDMA, recognized as a competitive inhibitor of
cellular L-Arg transport was also decreased after 1 and 2 months
of treatment with MNA or perindopril, but these changes did not
reach statistical significance. Moreover, reduced concentration of
methylated Arg was associated with an increase in the content of
Met and concomitant decrease in the level of Hcy. Consequently,
plasma L-Arg/ADMA ratio reflecting NO bioavailability was
clearly elevated after 1 month of treatment with both MNA
(by 34%) and perindopril (by 46%), and this effect was further
maintained after 2 months of treatment. Interestingly, there was
a significant correlation between L-arginine/ADMA ratio and
endothelium-dependent response of BCA or Npx50 (Table 1).
DISCUSSION
In the present work, we profiled endothelial activity of MNA
in comparison with perindopril (ACE-I) using functional 3D
MRI–based in vivo assays of endothelial function in parallel to
biochemical measurements of ACE/Ang II-ACE2/Ang-(1–7)
balance, and L-Arg/ADMA ratio in plasma. We demonstrated
in vivo in ApoE/LDLR−/− mice, that treatment with MNA
or perindopril resulted in the reversal of Ach-induced
vasoconstriction response to vasodilatation and a concomitant
decrease in endothelial permeability. Functional improvement
of endothelial function by MNA or perindopril treatment was
in both cases associated with the inhibition of ACE/Ang II axis
and parallel activation of ACE2/Ang-(1–7) axis as evidenced by
a fall in plasma concentration of Ang II, and its N-terminally
truncated metabolites (Ang III and IV) and an increase in
Ang-(1–9) and Ang-(1–7) plasma concentration. Furthermore,
MNA and perindopril treatment resulted in an increase in
L-arginine/ADMA ratio compatible with improvement of
NO-dependent endothelial function. Altogether, our results
suggest that MNA displayed a similar pattern of vasoprotective
activity as perindopril, a representative of ACE-Is, and both
compounds affected ACE/Ang II-ACE2/Ang-(1–7) balance and
L-Arg/ADMA ratio that could contribute to their vasoprotective
effects. Given that correction of endothelial function by ACE-Is
contributes significantly to their clinical benefits and their anti-
inflammatory, anti-thrombotic, anti-diabetic, and vasoprotective
actions reported in numerous experimental and clinical papers
(Chłopicki and Gryglewski, 2005), the findings of endothelial
profile of MNA being similar to perindopril in in vivo settings
bring important novel perspectives to understanding the
therapeutic efficacy of MNA reported previously (Gebicki et al.,
2003; Wozniacka et al., 2005; Chlopicki et al., 2007; Bartuś et al.,
2008; Bryniarski et al., 2008; Brzozowski et al., 2008; Watała et al.,
2009; Sternak et al., 2010; Przyborowski et al., 2015; Blazejczyk
et al., 2016; Jakubowski et al., 2016; Mateuszuk et al., 2016).
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FIGURE 3 | Effects of MNA and ACE-I (perindopril) treatment on plasma Ang profile in ApoE/LDLR−/− mice. Plasma Ang profile in non-treated
ApoE/LDLR−/− mice (columns with diagonal lines) and in ApoE/LDLR−/− mice treated with MNA (black columns) or perindopril (columns with vertical lines) for one
month (A: Untreated_5m n = 6, perindopril n = 5, MNA n = 5) or two months (B: Untreated_6m n = 6, perindopril n = 8, MNA n = 7). Statistics: one-way ANOVA
followed by Tukey’s post hoc test (normality was assessed using the Kolmogorov–Smirnov test); ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
In this study, endothelial function in vivo assessment was
performed in BCA, in response to intraperitoneal administration
of Ach. Importantly, endothelium-dependent response was
independent of the effect of Ach on the heart and respiration
(Bar et al., 2016). Undoubtedly, the important advantage of
the use of MRI-based method is a retrospective reconstruction
of images from 3D data sets, which allows for assessment of
response of the entire vessel instead of only one fragment of
the vessel. Moreover, the method provides the possibility of
accurate positioning after experiment, whereby the effects of
endothelial pharmacotherapy can be assessed, even in small
vessels such as BCA, across various cross-sections to be located
in planes perpendicular to the vessel. The 3D gradient echo
sequence allows the avoidance of precise slice positioning during
measurements, as arbitrary re-slicing during post-processing is
possible with shorter time of the measurements. Importantly, in
the present work an MRI-based method to assess endothelial
permeability changes was also employed. We assessed the
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FIGURE 4 | Effects of MNA and ACE-I (perindopril) treatment on L-arginine/ADMA ratio in plasma in ApoE/LDLR−/− mice. Plasma concentration of
L-Arg, its precursors (L-Cit, L-Orn), ADMA, SDMA, Met, Hcy as well as L-Arg/ADMA ratio in non-treated ApoE/LDLR−/− mice (columns with diagonal lines) and in
ApoE/LDLR−/− mice treated with MNA (black columns) or perindopril (columns with vertical lines) for one month (A: Untreated_5m n = 6, perindopril n = 5, MNA
n = 5) or two months (B: Untreated_6m n = 6, perindopril n = 8, MNA n = 7). Statistics: one-way ANOVA followed by Tukey’s post hoc test (normality was assessed
using the Kolmogorov–Smirnov test); ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
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number of pixels (around the BCA) for which T1 had changed
more than 50% (Npx50), as described previously (Bar et al.,
2016). Npx50 parameter allows avoiding precise determination
of ROI, what is difficult to establish objectively. Finding the pixels
for which T1 had changed more than 50%, allows for operator-
independent assessment of the ROI around the vessel. Analysis
of changes in endothelial permeability represents an important
feature of endothelial dysfunction, and its measurements seem
a valuable test to analyze endothelial state in vivo. When
endothelial permeability increases, leaky intercellular junctions of
endothelium allow access to low-density lipoprotein particles and
transmigration of leukocytes that are critical in atherosclerotic
plaque formation (Kao et al., 1995). Moreover, albumin-binding
CA can also accumulate in vessel walls (Lobbes et al., 2009;
Pedersen et al., 2011), and this results in shortening of the T1 in
the vessel wall enabling MRI-based detection, and Npx50-based
operator-independent assessment of endothelial permeability
(Bar et al., 2016). Importantly, in the present work, analysis of
endothelial-dependent response by Ach as well as endothelial
permeability based on Npx50 displayed significant negative
correlation and gave concordant results showing improvement
after MNA and perindopril treatment. Experiments carried out
in this paper support the notion that MRI-based technique
based on the retrospectively self-gated 3D IntraGate R© FLASH
sequence (Bar et al., 2016) is useful for monitoring the efficacy
of endothelium-targeted therapy in murine models of diseases
in vivo and seems far superior to ultrasound (Cavalcante et al.,
2011).
In non-treated ApoE/LDLR−/− mice, injection of Ach
resulted in paradoxical vasoconstriction, what was most likely
due to a smooth muscle muscarinic receptor-dependent
response, as also shown for human arteries with endothelial
dysfunction (Ludmer et al., 1986). Treatment with MNA
or perindopril resulted in shifting the Ach response to a
vasodilatation, which indicates improvement in endothelial
function. Comparing results of changes in BCA volume after
acetylcholine administration in 5-month-old C57BL/6J mice
(9.3%) published in our previous paper (Bar et al., 2016), to
ApoE/LDLR-/- mice after two-month treatment with MNA
(4.5%) or perindopril (5.5%) performed in present study, it
seems that either treatment considerably improved the impaired
endothelium-dependent response. It is worth noting that,
after one-month treatment effects of perindopril seemed to
be more pronounced as compared with the effect of MNA,
but this difference disappeared after two months of treatment.
Improvement in endothelial permeability was also similar in
magnitude for MNA and perindopril after two months of
treatment, supporting the similar pattern of endothelial response
to MNA given in a dose of 100 mg/kg b.w./day in comparison to
perindopril given in a dose of 10 mg/kg b.w./day.
An important finding of the present study was the
demonstration that improvement of endothelial function
by MNA and perindopril treatment, evidenced by MRI-based
assays, was in both cases associated with the inhibition of the
classical RAS pathway – ACE/Ang II/AT1R and concomitant
activation of counter-regulatory RAS pathway – ACE2/Ang-
(1–7)/Mas. Numerous previous studies clearly indicate that the
RAS plays a critical role in the initiation and progression of
atherosclerosis with endothelial dysfunction as its early event,
and that the balance between two major axes of RAS, i.e.,
ACE/Ang II and ACE2/Ang-(1–7), is a key determinant of RAS
beneficial vs. detrimental effects (Wang et al., 2013; Olkowicz
et al., 2015; Cahill and Redmond, 2016). Ang II is considered as
a pro-atherosclerotic mediator which causes vasoconstriction,
regulates adhesion molecule (ICAM-1, VCAM-1, P-selectin)
expression as well as chemokine, cytokine, and growth factor
secretion within the arterial wall (Jiang et al., 2014). On the
other hand, ACE2, through its product Ang-(1–7) displays
anti-atherosclerotic properties in vivo, including decreasing
inflammation and oxidative stress, and inhibiting inflammatory
cell infiltration. The protective effect of ACE2, mainly distributed
in ECs, VSMCs, and macrophages, was repeatedly demonstrated.
Overexpression of ACE2 by gene transfer attenuated the
progression of atherosclerotic lesions when the ACE2 gene
was transferred 4 weeks after injury in a rabbit model of
atherosclerosis (Dong et al., 2008). Similarly, overexpression of
ACE2 in ApoE-deficient mice decreased atherosclerotic lesion
size within the aortic sinus as compared to control mice (Lovren
et al., 2008). In contrast, ACE2-deficiency in LDLR−/− as well as
ApoE−/− genetic background mice increased the development
of atherosclerosis (Thomas et al., 2010; Thatcher et al., 2011).
Our results not only confirmed that perindopril-induced
a vasoprotective shift in the balance of ACE/Ang II and
ACE2/Ang-(1–7), but also underscored that the profile of
MNA is similar to that exerted by perindopril. Zhuo et al.
(2002) have recently demonstrated that the clinical benefits
of chronic ACE inhibition with perindopril, in addition to
the blockade of systemic and tissue Ang II formation, may
be in part due to elevated bradykinin levels, which in turn
lead to increased NO bioavailability. Bradykinin was shown
to be the major mediator of ACE-I-induced anti-thrombotic
effects (Gryglewski et al., 2003, 2005; Chłopicki and Gryglewski,
2005). We did not study here the relative contribution
of Ang II–dependent and bradykinin–dependent pathway to
perindopril-induced improvement in NO-dependent function,
but obviously it cannot be excluded that both pathways may
be involved in perindopril-induced improvement in endothelial
function. Whether the same mechanisms contribute to MNA-
induced effects remains to be established. Interestingly, in
our previous studies describing anti-atherosclerotic effects of
MNA, an improvement in NO–dependent endothelial function,
observed in ex vivo vascular preparations was also associated with
activation of PGI2–dependent function (Mateuszuk et al., 2016).
Altogether, the results presented here suggest that MNA- induced
shift in the balance of ACE/Ang II and ACE2/Ang-(1–7) toward
the vasoprotective axis may contribute to the improvement of
endothelial function by MNA or alternatively may constitute
an important pathophysiological sign of improved endothelial
function.
We also demonstrated that MNA and perindopril treatment
resulted in an increase in L-arginine/ADMA ratio that was
compatible with improvement of NO-dependent endothelial
function. Given the fact, that circulating level of ADMA
adds independent prognostic information with regard to
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cardiovascular risk beyond that obtained from classical risk
factors and novel biomarkers (Schnabel et al., 2005) this
finding is of importance. In fact, plasma concentrations of
ADMA have been found to be significantly elevated in patients
with arteriosclerosis, as well as in those with coronary risk
factors, such as hypertension or hypercholesterolemia, and
marked increase in ADMA level has been associated with
impaired endothelium-dependent NO-mediated vasodilatation
(Böger et al., 1997, 1998; Surdacki et al., 1999; Böger, 2003)
that may be linked to decreased activity of y+LAT as the
major export pathway for the ADMA (Closs et al., 2012).
Interestingly, Suda et al. (2004) have recently reported that the
long-term vascular effects of ADMA are not solely mediated
by inhibition of endothelial NO synthesis but also can lead to
direct upregulation of ACE expression and increased oxidative
stress through AT1 receptor activation. Moreover, they have
proposed that inhibition of NO synthesis appears primarily as
a result of short-term action of ADMA; as long as metabolites
of ADMA accumulate at higher concentrations in blood vessels,
eNOS-independent mechanisms predominate. Involvement of
multiple mechanisms in vascular effects of ADMA, other than
simple inhibition of endothelial NO synthesis, including also
upregulation of ACE, remains to be clarified. In a recent work
of Jiang et al. (2016) it was reported that MNA attenuated
atherogenesis via modulation of the ADMA-DDAH pathway in
ApoE-deficient mice. The beneficial effect of MNA treatment
was associated with the upregulation of the DDAH2 enzyme
activity in endothelium via the mitigation of hypermethylation
in the promoter region of the enzyme. These results seem
consistent with our observations showing the reduction in
plasma ADMA concentration as well as Hcy concentration that
was linked to an improved endothelium-dependent vascular
relaxation after MNA. Interestingly, Huang et al. (2015) showed
that Hcy synthesized in endothelium (after Met administration)
affected activity of ACE by direct homocysteinylation of its
amino- and/or sulfhydryl- moieties. This modification enhanced
ACE reactivity toward Ang II and consequently led to NADPH
oxidase-superoxide-dependent endothelial dysfunction. In that
context, treatment with MNA and perindopril attenuates various
apparently interlinked biochemical changes closely associated
with functional phenotype of endothelial dysfunction such as
excessive activation of ACE, elevation of ADMA and Hcy that
can all contribute to vasoprotective action of these compounds
resulting in the improvement of endothelial function reported
here in vivo using functional and biochemical measurements.
Indeed, there was a significant positive correlation between
endothelium-dependent response of BCA after acetylcholine
administration and the two major biochemical parameters
measured here [L-arginine/ADMA ratio and Ang-(1–7)/Ang II].
In turn, since the improvement of endothelial dysfunction was
associated with a decrease in endothelial permeability, correlation
between Npx50 and biochemical parameters [L-arginine/ADMA
ratio and Ang-(1–7)/Ang II] had negative character. Similar
correlations between ADMA concentration and Ach- or flow-
induced vasodilatation have also been demonstrated previously
in monkeys with hypercholesterolemia, using endothelium-
dependent vascular function ex vivo assessment (Böger et al.,
2000) as well as in humans with hypercholesterolemia using
ultrasonography ( Böger et al., 1998).
Effects of treatment with MNA and perindopril on
atherosclerotic plaque burden were not assessed in this study, but
it was reported previously that perindopril treatment inhibited
the development of atherosclerotic lesions in diabetic ApoE-
deficient mice (Candido et al., 2002), while anti-atherosclerotic
effect of MNA was described in apolipoprotein E (ApoE)/low-
density lipoprotein receptor (LDLR)-deficient mice (Mateuszuk
et al., 2016). Given the pathophysiological role of endothelial
dysfunction in atherogenesis, effects of MNA or perindopril on
endothelial function could contribute to the anti-atherosclerotic
action of these compounds.
CONCLUSION
Using functional 3D MRI-based assays of endothelial function
and biochemical measurements of ACE/Ang II, ACE2/Ang-(1–7)
balance and L-Arg/ADMA ratio in plasma, we demonstrated
significant vasoprotective effects of MNA (100 mg/kg b.w./day),
which were comparable with that afforded by perindopril
(10 mg/kg b.w./day), a well-known ACE inhibitor. Although
effects of MNA were less pronounced as compared with
perindopril after 1-month treatment, after 2-month treatment,
either treatment modality resulted in a comparable effect
including reversal of Ach-induced vasoconstriction response
to vasodilatation and a concomitant decrease in endothelial
permeability. Furthermore, functional improvement of
endothelial function by MNA or perindopril treatment was
in both cases associated with the inhibition of ACE/Ang II axis,
the parallel activation of ACE2/Ang-(1–7) axis, and an increase
in L-Arg/ADMA ratio in plasma. Given that improvement in
endothelial function by ACE-Is contributes to their therapeutic
efficacy (Chłopicki and Gryglewski, 2005), presented in the
current study findings of endothelial profile of MNA being
similar to ACE-I (perindopril) in in vivo settings bring important
novel perspectives to understand therapeutic efficacy of MNA
(Gebicki et al., 2003; Wozniacka et al., 2005; Chlopicki et al.,
2007; Bartuś et al., 2008; Bryniarski et al., 2008; Brzozowski et al.,
2008; Watała et al., 2009; Sternak et al., 2010; Przyborowski et al.,
2015; Blazejczyk et al., 2016; Jakubowski et al., 2016; Mateuszuk
et al., 2016). Moreover, our approach for the in vivo assessment
of endothelial phenotype based on a retrospectively self-gated 3D
gradient-echo sequence, MRI-based technique, concomitant with
the biochemical assays of two important systems of endothelial
regulation, ACE/Ang-II-ACE2/Ang-(1–7) and L-Arg/ADMA,
proves to be a useful tool for the in vivo endothelial profiling of
compounds to demonstrate convincingly their beneficial effects
on endothelial function.
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